If your portfolio needs a health check, then the healthcare sector could be just what the doctor ordered.
ASX 200 healthcare shares have a history of delivering strong, long-term returns thanks to consistent demand, pricing power, and innovation.
While some areas of the market are prone to wild swings, healthcare companies tend to offer a more stable prognosis—after all, people will always need medical treatments, diagnostics, and life-saving drugs.
With that in mind, let's take a closer look at three top ASX 200 healthcare shares that could inject strong returns into your portfolio over the long run.
CSL is the undisputed heavyweight of the ASX healthcare sector, and for good reason. The biotechnology giant is a global leader in plasma therapies, vaccines, and life-saving treatments for rare diseases.
Despite recent challenges, including plasma collection disruptions during the pandemic, CSL is showing strong signs of recovery.
This has caught the eye of analysts at Goldman Sachs. The broker recently put a buy rating and $307.30 price target on its shares.
With a rock-solid track record of innovation and reinvestment, CSL could be a prescription for long-term wealth creation.
If you're looking for a high-growth ASX 200 healthcare share with cutting-edge technology, Pro Medicus could be the perfect remedy.
The health imaging technology company provides cloud-based imaging solutions to some of the biggest hospitals in the world.
Its Visage software is faster and more efficient than traditional imaging systems, allowing radiologists to diagnose patients more quickly. With contracts locked in across North America and Europe, and a growing pipeline of deals, Pro Medicus continues to be a high-margin, high-growth healthcare stock with a bright future.
It is no wonder then that Bell Potter has a buy rating and $330.00 price target on its shares.
Finally, sleep apnoea might not be a hot topic at dinner parties, but for millions of people worldwide, it is a serious issue.
That's where this ASX 200 healthcare share comes in. ResMed is a global leader in sleep and respiratory care solutions, helping people with sleep disorders and chronic respiratory conditions breathe easier.
Goldman Sachs is extremely positive on ResMed's growth outlook. So much so, its analysts recently put a conviction buy rating and $49.00 price target on its shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.